Quest Laboratories Limited
Founded in June 1998, Quest Laboratories Limited produces a diverse range of pharmaceuticals, including antibiotics, antimalarials, anti-inflammatories, etc.
What Quest files
- Others37
- Important31
- Investor Meet22
- Board Meeting10
- PPTs3
- Updates3
Quest Laboratories' board approved its 28th AGM for Sep 30, 2026, to adopt the financial results for FY26. Key decisions include re-appointing Director Smt. Tejaswini Sabarwal, appointing M/s C.H. Padliya & Co. as Statutory Auditors, and ratifying Cost Auditor fees at Rs. 50,000 p.a.
Quest Laboratories' Board approved audited standalone FY26 results: PAT ₹14.89 Cr, EPS ₹9.16. No dividend declared. The company also acquired land for ₹3.21 Cr for manufacturing expansion & approved new internal, secretarial, and cost auditors for FY27.
Quest Laboratories' Board approved the standalone financial results for the quarter and half-year ended Sep 30, 2025. They also approved a postal ballot for the appointment of their Statutory Auditor.
Quest Laboratories' board approved the financial results for the quarter and half-year ended September 30, 2025. They also approved the notice for a postal ballot regarding the appointment of the Statutory Auditor.
Quest Laboratories' board approved its financial results for the quarter ended June 30, 2025. The company reported a significant profit for the period of ₹4.10 Cr, a strong increase from ₹1.94 Cr last quarter and ₹1.48 Cr a year ago. Revenue from operations stood at ₹23.18 Cr, down from last...